Secondary prevention of stroke in patients with atrial fibrillation: Factors influencing the prescription of oral anticoagulation at discharge

被引:26
作者
Deplanque, Dominique [1 ]
Leys, Didier
Parnetti, Lucilla
Schmidt, Reinhold
Ferro, Jose
de Reuck, Jacques
Mas, Jean-Louis
Gallai, Virgilio
机构
[1] Fac Med Lille, Dept Pharmacol, F-59045 Lille, France
[2] Fac Med Lille, Dept Neurol, F-59045 Lille, France
[3] Univ Perugia, Dept Neurosci, I-06100 Perugia, Italy
[4] Graz Univ, Dept Neurol, A-8010 Graz, Austria
[5] Hosp Santa Maria, Dept Neurosci & Mental Hlth, Lisbon, Portugal
[6] Ghent Univ Hosp, Dept Neurol, B-9000 Ghent, Belgium
[7] Hop St Anne, Dept Neurol, F-75674 Paris, France
关键词
stroke; atrial fibrillation; secondary prevention; oral anticoagulation; antiplatelet drugs;
D O I
10.1159/000091546
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Oral anticoagulation (OAC) is the only treatment that has shown a significant benefit to reduce the risk of recurrence in patients with ischemic stroke and nonvalvular atrial fibrillation (NVAF). However, OAC is still underused, even at discharge from neurological centers. The objective of this study was to identify the reasons underlying the prescription of OAC at discharge after an ischemic stroke in patients with NVAF. Methods: We investigated the reasons why ischemic stroke patients with NVAF were not treated with OAC at discharge from 40 centers located in 5 European countries (Austria, Belgium, France, Italy, and Portugal). Results: Of 320 ischemic stroke survivors at discharge, 186 (58.1%) received OAC, while 260 (81.3%) patients were theoretically eligible according to guidelines and the absence of contraindications. There were significant differences between countries and the logistic regression analysis found being already under OAC before stroke, having no leuko-araiosis, having no potential contraindication, being younger than 75 years, being married and suffering from angina pectoris as independent predictors of being discharged under OAC. Conclusion: This study suggests that besides patient-related factors, the prescription of OAC is also significantly influenced by the social environment and national practices. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:372 / 379
页数:8
相关论文
共 36 条
[21]  
KOUDSTAAL PJ, 1993, LANCET, V342, P1255
[22]   Antithrombotic drugs in secondary stroke prevention among a community dwelling older population [J].
Landi, F ;
Cesari, M ;
Onder, G ;
Zamboni, V ;
Lattanzio, F ;
Russo, A ;
Barillaro, C ;
Bernabei, R .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08) :1100-1104
[23]   Prestroke dementia in patients with atrial fibrillation -: Frequency and associated factors [J].
Lefebvre, C ;
Deplanque, D ;
Touzé, E ;
Hénon, H ;
Parnetti, L ;
Pasquier, F ;
Gallai, V ;
Leys, D .
JOURNAL OF NEUROLOGY, 2005, 252 (12) :1504-1509
[24]   Prevention [J].
Leys, D ;
Kwiecinski, H ;
Bogousslavsky, J ;
Bath, P ;
Brainin, M ;
Diener, HC ;
Kaste, M ;
Sivenius, J ;
Hennerici, MG ;
Hacke, W .
CEREBROVASCULAR DISEASES, 2004, 17 :15-29
[25]   Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting [J].
McCormick, D ;
Gurwitz, JH ;
Goldberg, RJ ;
Becker, R ;
Tate, JP ;
Elwell, A ;
Radford, MJ .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (20) :2458-2463
[26]   How well does the Oxfordshire Community Stroke Project classification predict the site and size of the infarct on brain imaging? [J].
Mead, GE ;
Lewis, SC ;
Wardlaw, JM ;
Dennis, MS ;
Warlow, CP .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (05) :558-562
[27]   Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk? [J].
Monesi, L ;
Avanzini, F ;
Barlera, S ;
Caimi, V ;
Lauri, D ;
Longoni, P ;
Roccatagliata, D ;
Tombesi, M ;
Tognoni, G ;
Roncaglioni, MC .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (08) :595-601
[28]   SILENT INFARCTS IN PATIENTS WITH ISCHEMIC STROKE ARE RELATED TO AGE AND SIZE OF THE LEFT ATRIUM [J].
MOUNIERVEHIER, F ;
LEYS, D ;
RONDEPIERRE, P ;
GODEFROY, O ;
PRUVO, JP .
STROKE, 1993, 24 (09) :1347-1351
[29]   Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT) [J].
Palareti, G ;
Leali, N ;
Coccheri, S ;
Poggi, M ;
Manotti, C ;
DAngelo, A ;
Pengo, V ;
Erba, N ;
Moia, M ;
Ciavarella, N ;
Devote, G ;
Berrettini, M ;
Musolesi, S .
LANCET, 1996, 348 (9025) :423-428
[30]   Atrial fibrillation as a risk factor for stroke recurrence [J].
Penado, S ;
Cano, M ;
Acha, O ;
Hernández, JL ;
Riancho, JA .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (03) :206-210